Transmeta Announces Processor Technology License and Sale Agreement for the Chinese Market; Agreement to Deliver Transmeta Cruso
2005年5月31日 - 7:00PM
ビジネスワイヤ(英語)
Transmeta Corporation (Nasdaq:TMTAE), the leader in efficient
computing technologies, today announced the signing of asset
purchase and license agreements with Culture.com Technology Limited
(Culturecom), a fully owned subsidiary of Culturecom Holdings Ltd
(343.HK), a Hong Kong based technology company. This transaction is
subject to the completion of a number of conditions, including the
receipt of a technology export license from the U.S. Department of
Commerce, certain other third party consents and the signing of a
related services agreement with Transmeta. Pursuant to these
agreements, Transmeta has agreed to sell, through a combination of
asset purchase and licensing agreements, its Crusoe(TM) product
line to Culturecom. As part of this agreement, Culturecom will also
license Transmeta's 130-nanometer Efficeon(TM) technology to make
and sell Efficeon-based products in China. In consideration,
Culturecom will make up-front cash payments totaling $15 million to
be escrowed pending the close of the transaction. In addition to
the up-front payments, Culturecom will also pay royalties to
Transmeta on sales by Culturecom of Crusoe and Efficeon products.
The transaction is scheduled to close in the fourth quarter of
2005. "This engagement helps deliver Transmeta processor technology
to the rapidly growing Chinese computing market through Culturecom,
an established provider of Chinese-language technology solutions,"
said Arthur L. Swift, president and chief executive officer of
Transmeta. "This relationship is another example of Transmeta's
commitment to deploy our innovative technologies through licensing
and synergistic engineering services." As part of this transaction,
Culturecom will also enter into an engineering services agreement
with Transmeta to facilitate the transfer of the technology.
Previously, Culturecom licensed Transmeta's Midori Linux for the
development of embedded applications and, in conjunction with that
license, Transmeta acquired, and continues to own, a minority
equity stake in Chinese 2 Linux (Holdings) Limited, an affiliate of
Culturecom. "This agreement expands Culturecom's ongoing business
of providing processors with embedded Chinese language technology,"
said Frank W. T. Cheung, chairman and chief executive officer of
Culturecom. "Transmeta's unique x86-compatible processor
architecture coupled with Culturecom's Chinese language technology
will facilitate the adoption of modern computing technology by
mainstream Chinese consumers." Transmeta will continue to
manufacture its Crusoe and 130-nanometer Efficeon products until
the transaction closes, and will complete fulfillment of existing
backlog in the subsequent transition period. As previously
announced, Transmeta will continue to support its 90-nanometer
Efficeon processors for Transmeta's strategic partners. About
Transmeta Corporation Transmeta Corporation develops and licenses
innovative computing, microprocessor and semiconductor technologies
and related intellectual property. Founded in 1995, Transmeta first
became known for designing, developing and selling its highly
efficient x86-compatible software-based microprocessors, which
deliver a balance of low power consumption, high performance, low
cost and small size suited for diverse computing platforms. We also
develop advanced power management technologies for controlling
leakage and increasing power efficiency in semiconductor and
computing devices. To learn more about Transmeta, visit
www.transmeta.com. Safe Harbor Statement This release contains
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements speak only as of the date of this release, and we
will not necessarily provide updates of our projections or other
forward-looking statements. Investors are cautioned that such
forward-looking statements are subject to many risks and
uncertainties, and may differ materially or adversely from our
actual results or future events. Important risk factors that could
have material or adverse effects on our results include
satisfaction of the closing conditions to the transaction, the
expected timetable for completing the transaction, general economic
and political conditions, specific conditions and volatility in the
markets that we address, difficulties or delays in implementing our
restructuring plan, the potential loss of key technical and
business personnel resulting from our restructuring plan, practical
challenges in modifying our business model, our ability to satisfy
the continued listing requirements of the Nasdaq Stock Market, the
adoption and market acceptance of our products and technologies by
current and potential customers and licensees, our inability to
predict or ensure that third parties will license our technologies
or use our technologies to generate royalties, the rescheduling or
cancellation of significant customer orders, difficulties in
developing or manufacturing our products in a timely and cost
effective manner, our dependence on third parties for sourcing
materials and providing manufacturing services, intense competition
and competitive pressures, the ability to enter strategic
collaborations or raise financing on satisfactory terms, patents
and other intellectual property rights, and other risk factors. We
urge investors to review our filings with the Securities and
Exchange Commission, including our most recent reports on Forms
10-K, 10-K/A and 10-Q, which describe these and other important
risk factors that could have an adverse effect on our results. We
undertake no obligation to revise or update publicly any
forward-looking statement for any reason. Transmeta, Efficeon,
LongRun2 and Crusoe are trademarks of Transmeta Corporation. All
other product or service names mentioned herein are the trademarks
of their respective owners.
Transmeta (NASDAQ:TMTAE)
過去 株価チャート
から 9 2024 まで 10 2024
Transmeta (NASDAQ:TMTAE)
過去 株価チャート
から 10 2023 まで 10 2024